 |
|
|
|
|
|
|
|
 |
Results for 'Novartis AG - Deals and Alliances Report' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Novartis AG -Deals & Alliances Report
|
February 2008 |
£300 |
100 % |
Partneringdesk deals and alliances in cardiovascular diseases
|
April 2006 |
£1250 |
42 % |
Partneringdesk deals and alliances in metabolic diseases
|
April 2006 |
£1250 |
41.5 % |
Partneringdesk deals and alliances in genitourinary and gynecological diseases
|
April 2006 |
£1250 |
41.5 % |
Partneringdesk deals and alliances in gastrointestinal diseases
|
April 2006 |
£1250 |
41.5 % |
Partneringdesk deals and alliances in musculoskeletal diseases
|
April 2006 |
£1250 |
41.5 % |
Partneringdesk deals and alliances in autoimmune & inflammatory diseases
|
April 2006 |
£1250 |
40.5 % |
Partneringdesk deals and alliances in sensory and dental diseases
|
April 2006 |
£1250 |
40.5 % |
Pharmaceutical Strategic Alliances
Maximizing returns from collaborative development and commercialization
|
September 2006 |
£1495 |
35 % |
Novartis AG -Detailed Product Pipeline
|
February 2008 |
£375 |
33.5 % |
Effective Licensing & Commercialisation of Drug Delivery Systems
2006
|
July 2006 |
£2500 |
29.75 % |
Pharmaceutical Licensing Strategies
Best practices in deal-making, valuations and strategic management
|
June 2006 |
£1495 |
29.4 % |
Late Stage Deals
Strategy, Structure and Payment Terms
|
August 2004 |
£950 |
28.5 % |
Partneringreview 2006 – Deal Type
Volume 5
|
February 2006 |
£1395 |
27 % |
Partneringreview 2006 – Stage of Development
Volume 4
|
February 2006 |
£1395 |
27 % |
Partneringreview 2006 – Industry Sector
Volume 6
|
February 2006 |
£1395 |
27 % |
Partneringreview 2006
|
February 2006 |
£2195 |
27 % |
Manufacturing & Supply Agreements in Biopharma
|
April 2008 |
£1195 |
26.6 % |
Partneringreview 2006 – Financings
Volume 3
|
February 2006 |
£1395 |
26.5 % |
Partneringreview 2006 – Therapy Area
Volume 2
|
February 2006 |
£1395 |
26.5 % |
Co-promotion & Co-marketing Agreements in Biopharma
|
January 2008 |
£1195 |
26.25 % |
Partneringreview 2006 - Company Deal Index
Volume 1
|
February 2006 |
£1395 |
25.5 % |
Distribution Agreements in Biopharma
|
April 2008 |
£1195 |
25.2 % |
Merger & Acquisition Agreements in Biopharma
|
February 2008 |
£1195 |
23.8 % |
Licensing Strategies - Examining Todays Pharmaceutical Licensing Trends
|
November 2007 |
£7600 |
22.05 % |
Sandoz Generics Company Intelligence Report
Company Intelligence Report
|
June 2008 |
£195 |
20 % |
The Pharmaceutical Market Outlook to 2015
Implementing innovative, long-term strategies for sustainable future growth
|
January 2005 |
£1495 |
18.2 % |
Strategies for Innovation in Pharmaceutical R&D
Enhancing R&D Through Biotech Alliances and CRO Outsourcing
|
March 2005 |
£370 |
17.15 % |
Early Stage and Discovery Deals
Strategy, Structure and Payment Terms 2nd Edition
|
January 2007 |
£1350 |
16.8 % |
Drug Delivery Systems
US Market Outlook, Advances for Pharma, Biotech & Medical Devices
|
September 2006 |
£1140 |
16.45 % |
Molecular Diagnostics 2007
Technologies, Companies, Products, Applications and Worldwide Outlook
|
May 2007 |
£1255 |
15.75 % |
Commercializing Molecular Diagnostics:
Products, Services, Companies and Global Market
|
July 2008 |
£1295 |
15.75 % |
Winning R&D Productivity Strategies
Exploiting innovation, licensing and outsourcing opportunities
|
October 2006 |
£1495 |
15.4 % |
Beyond the Blockbuster Drug
Strategies for nichebuster drugs, targeted therapies and personalized medicine.
|
February 2005 |
£1495 |
15.05 % |
World Neurodegeneratives Disease Markets
|
February 2005 |
£1499 |
14.5 % |
MorphoSys Ag
Premium Company Profile
|
April 2008 |
£265 |
14.5 % |
Monoclonal Antibodies Report Part II
Companies - Holding Mabs In Portfolio Promises Protection Against The Looming 2011-12 Patent Cliff
|
September 2007 |
£3800 |
14.35 % |
Pharmaceutical Parallel Trade in the United Kingdom, 2000-2006
Market Insights and Trends in a Primary Import Destination
|
August 2006 |
£900 |
13.5 % |
The Vaccines 2008
World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry
|
April 2008 |
£2070 |
11.55 % |
Targeted Therapies in Oncology
A World Review
|
December 2006 |
£3360 |
11.55 % |
Brazil Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
11.2 % |
South Africa Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
11.2 % |
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007
|
June 2007 |
£1999 |
11 % |
Ion Channel Drug Discovery
Therapeutic Opportunities & Technology Progress
|
May 2004 |
£680 |
11 % |
Bariatric (Obesity) Care Equipment & Surgical Devices Worldwide
A Market Strategy Report
|
February 2006 |
£990 |
11 % |
Netherlands Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
10.85 % |
Pipeline Insight Asthma/COPD/Allergic Rhinitis
As Patents Expire, Novel Combinations Inspire
|
April 2005 |
£6000 |
10.85 % |
China Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
10.85 % |
Australia Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
10.5 % |
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology
|
December 2006 |
£3510 |
10.5 % |
Advanced Drug Delivery Systems: Probing the Route to Growth
New Developments, New Technologies, Companies and Trends
|
October 2001 |
£705 |
10.15 % |
KRKA Generics Company Intelligence Report
Company Intelligence Report
|
June 2008 |
£195 |
10 % |
Vaccines: The World Market
|
February 2007 |
£2015 |
9.8 % |
Generic Option; The
|
July 2006 |
£440 |
9.8 % |
World Market for Vaccines, The
|
November 2004 |
£2015 |
9.8 % |
Decoding Big Pharmas R&D Strategy in Oncology
|
September 2007 |
£2495 |
9.8 % |
Vaccines
The World Market
|
February 2007 |
£2015 |
9.8 % |
Ranbaxy Generics Company Intelligence Report
Company Intelligence Report
|
June 2008 |
£195 |
9.45 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1665 |
9.45 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1665 |
9.45 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1665 |
9.45 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1665 |
9.45 % |
Brazil Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
9.45 % |
South Africa Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
9.45 % |
Japan Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
9.45 % |
Spain Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
9.45 % |
UK Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
9.45 % |
Italy Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
9.45 % |
AMD Market Outlook to 2012
|
March 2007 |
£1299 |
9.1 % |
Top 10 Generic Pharmaceutical Companies, The
Positioning, Performance and SWOT Analyses
|
July 2008 |
£1995 |
9.1 % |
Drug Delivery Technology: Revolutionizing Cardiovascular Therapies
|
July 2007 |
£945 |
9 % |
Netherlands Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
8.75 % |
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents
|
October 2006 |
£2340 |
8.75 % |
Australia Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
8.75 % |
Indian Pharmaceutical Industry, The:
|
March 2005 |
£3335 |
8.75 % |
The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023
|
June 2008 |
£1499 |
8.4 % |
UK Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
8.05 % |
South Africa Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1625 |
8.05 % |
World’s Top Ten Generic Companies
|
November 2005 |
£1999 |
8.05 % |
Italy Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
8.05 % |
Strategies for Biogeneric Success
|
June 2004 |
£950 |
8.05 % |
Japan Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
8.05 % |
Brazil Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1625 |
8.05 % |
Bayer Schering Pharma Ag
PharmaVitae Profile
|
July 2008 |
£2995 |
8.05 % |
China Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1625 |
7.7 % |
U.S. and Worldwide Monoclonal Antibody Medicine
Current Status and Future Trends
|
August 2008 |
£590 |
7.7 % |
Netherlands Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1625 |
7.7 % |
Early Toxicology
Markets and Approaches
|
June 2007 |
£1765 |
7.35 % |
Rimonabant: The first of the Cannabinoid blockbusters
|
June 2007 |
£1499 |
7.35 % |
Australia Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1625 |
7.35 % |
Pharmaceutical Distribution in Europe
The Emergence of Direct-to-Pharmacy Supply
|
February 2008 |
£995 |
7.35 % |
Angiogenesis Modulators
|
January 2008 |
£1390 |
7.35 % |
Scrip R&D Databook 2006
|
January 2006 |
£1295 |
7 % |
Indian Pharmaceutical Industry
|
July 2008 |
£1695 |
7 % |
Nanotechnology
Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics
|
January 2008 |
£1995 |
7 % |
Vaccines
|
March 2008 |
£600 |
7 % |
Drug Delivery Technology: Revolutionizing CNS Therapies
|
December 2007 |
£945 |
7 % |
Winning Pharmaceutical Brand Management
Maximizing brand value through best practice in brand development and product marketing
|
March 2006 |
£1495 |
6.3 % |
Orphan Drugs to 2008
Understanding regulation & market opportunity in Europe
|
January 2005 |
£800 |
6.3 % |
Next-Generation Nutraceuticals
Food and pharma convergence in disease prevention and personalized nutrition
|
December 2006 |
£1495 |
5.95 % |
World Biotech Market 2005, The
|
June 2005 |
£4999 |
5.95 % |
Pfizer - Market Outlook for a Global Leader, 2008-2013
|
August 2008 |
£0 |
5.6 % |
F. Hoffmann-La Roche Ltd. Medical Equipment Company Share Analysis
|
September 2008 |
£570 |
5.25 % |
Generic League
Market Analysis and Forecasts, 2007-2012, 2017 & 2022
|
February 2008 |
£1999 |
5.25 % |
Apoptosis
|
January 2008 |
£1440 |
5.25 % |
Commercial Insight: Antibacterials
Pharma Strikes Antibac
|
August 2005 |
£8000 |
4.9 % |
Global Market for Antimicrobials and Antifungals; The
Challenging Resistance to 2016
|
December 2006 |
£1600 |
4.9 % |
The Pharmaceutical Market: UK
|
January 2007 |
£595 |
4.9 % |
Blood
The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products
|
September 2006 |
£1970 |
4.55 % |
Epigenomics
Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics
|
March 2007 |
£2410 |
4.2 % |
Pharmaceutical Outsourcing Strategies
Market expansion, offshoring and strategic management in the CRO and CMO marketplace
|
April 2006 |
£1495 |
4.2 % |
Stem Cell Research
|
January 2008 |
£2110 |
4.2 % |
Schering AG
Prospects to 2010
|
November 2006 |
£895 |
3.85 % |
Parkinson's Disease Market analysis and forecasts
2008-2012, 2017 & 2022
|
January 2008 |
£1499 |
3.85 % |
Therapeutic Monoclonal Antibodies Report 2008-2023
|
July 2008 |
£0 |
3.85 % |
Online Pharmaceutical Industry, 2006-2011, The
|
July 2006 |
£1499 |
3.5 % |
Clinical Nutrition Products: World Market, 2nd. Edition
|
August 2007 |
£1765 |
3.15 % |
GSK's Cervarix
A Future Blockbuster of 2007
|
March 2007 |
£1999 |
3.15 % |
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012
|
April 2007 |
£1499 |
2.8 % |
In-Vitro Diagnostics Market Report & Analysis 2008-2023
|
June 2008 |
£1499 |
2.8 % |
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012
|
April 2007 |
£1499 |
2.8 % |
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012
|
April 2007 |
£1499 |
2.8 % |
In Vitro Diagnostics Market Report & Analysis 2008-2023
|
June 2008 |
£1499 |
2.8 % |
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012
|
April 2007 |
£1499 |
2.8 % |
Gastrointestinal Endoscopy Systems and Instruments
A Market Strategy Report
|
March 2006 |
£740 |
2.45 % |
Antiageing and Life Enhancement Pharmacotherapeutics
|
January 2006 |
£4600 |
2.45 % |
The Executive Guide to Molecular Imaging
|
July 2007 |
£595 |
2.45 % |
Cancer Therapeutics: The Worldwide Market
The Worldwide Market , 2nd Editon
|
February 2007 |
£2015 |
2.1 % |
Infusion Pumps Worldwide
A Market Strategy Report
|
July 2006 |
£990 |
2.1 % |
|
|
|
|
